Accessibility Tools

Authors: Paul D. Holtom, MD, Charalampos Zalavras, MD, Kenneth C. Lamp, PharmD, Nami Park, PharmD, Lawrence V. Friedrich, PharmD

Title: Clinical Experience with Daptomycin for Foot or Ankle Osteomyelitis

Addresses: Univ. of Southern Calif. Keck School of Medicine, Los Angeles, CA; Cubist Pharmaceuticals, Lexington, MA

Purpose: Daptomycin is a novel antibiotic recently approved in May 2006 for Staphylococcus aureus bloodstream infections including right-sided infective endocarditis and previously for complicated skin and skin structure infections in 2003. The purpose of this analysis is to describe data for osteomyelitis from a registry.

Methods: Cubicin®Outcomes Registry and Experience (CORE 2004) is a multicenter, retrospective, observational chart review of characteristics and clinical outcome of daptomycin treated patients (pts) in 2004. Investigators collected demographic, disease state, clinical and microbiologic data as part of CORE 2004. In a followup study, investigators collected additional data including post-therapy outcomes. This analysis describes the results from pts with foot or ankle osteomyelitis.

Results: 25 patients with foot or ankle osteomyelitis were treated with daptomycin at an average dose of 5.4 mg/kg (range, 4.0-6.2 mg/kg) and average duration of therapy of 34 days (range, 6-59 days). The median follow-up interval was 69 days (range 3-540 days). A majority, 92%, had received daptomycin as secondary or tertiary therapy and 60% had failed prior antibiotic therapy. Diabetes was the most common underlying disease (40%). Concomitant antibiotics were given in 44%; primarily for Gram-negative and/or anaerobic coverage. Gram-positive pathogens, MRSA most common (55%), were identified in 22 (88%) patients; 64% monomicrobial, 24% polymicrobial. Outcomes (cure, improved, failure) at end of therapy were 64%, 32%, 4% and at follow-up were 76%, 12%, 12%. An average of 1.8 followup antibiotics were given to 13 (52%) pts for a median of 30 days (range 8-232 days); most frequently trimethoprim/ sulfamethoxazole, minocycline, rifampin, clindamycin and levofloxacin. The presence of diabetes or use of concomitant or followup antibiotics did not have a significant effect on outcomes. Four patients with an orthopedic devices (all removed) were successfully treated. Surgical bone debridement was performed in 68% and could have influenced success rates (94% with debridement vs 75% without debridement, P = 0.23). Success rates by dose were: =4 mg/kg (80%), >4 to <6 mg/kg (86%) and =6 mg/kg (92%); however, these differences were only observed in the group that did not receive bone debridement.

Discussion: Daptomycin appears successful for foot and ankle osteomyelitis caused by Gram-positive bacteria (including MRSA) particularly when used with higher doses and surgical intervention. Prospective, controlled clinical trials of daptomycin for osteomyelitis are warranted.

Musculoskeletal Infecton Society
Musculoskeletal Infecton Society
P.O. Box 422
Rochester, MN 55903-0422